

## **OPTIMIZING THE STATE OF THE IMMUNE SYSTEM, MODERN DIAGNOSIS AND TREATMENT IN CHILDREN WITH A BACKGROUND OF HYPERSENSITIVITY TO DRUGS**

**Yamgurova Ozoda Rajabturdievna**

*Bukhara State medical institute*

[yomgurovaozoda@gmail.com](mailto:yomgurovaozoda@gmail.com)

**Abstract:** Pediatric drug hypersensitivity is a rapidly evolving field. The purpose of this paper is to review the current state of pediatric drug hypersensitivity and highlight new developments in diagnosis and management.

**Research results:** This paper will discuss the safety and use of risk stratification to proceed directly to oral challenge without prior skin testing for  $\beta$ -lactam reactions. We review unique aspects of pediatric drug challenges and desensitizations. It is important to accurately diagnose pediatric drug hypersensitivity reactions through a detailed history, physical examination, and available diagnostic testing. Understanding of the underlying mechanism leads to appropriate classification which is necessary to direct management. The decision to perform drug challenge, desensitization, or recommend avoidance of a medication can have a significant impact on a patient's treatment. Utilization of weight-based dose and infusion rate adjustments for current drug challenge and desensitization protocols optimize success.

**Key words:** *desensitization, drug allergy, drug hypersensitivity, medication allergy, pediatric.*

### **INTRODUCTION**

An adverse drug reaction (ADR) is defined as any noxious and unintended response to a drug, which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease or modification of physiological function. A conservative estimate of the rate of ADRs in the general population is 5% per course of treatment, however; it can be as high as 50%, for example, in the case of cancer chemotherapy. [1,2] ADRs are a leading cause of morbidity and mortality in patients from all age groups [3,4,5] Serious ADRs occur at a rate of 6.7% in hospitalized patients and 0.32% of them are fatal. A review of 17 prospective studies of incidence rate of ADRs in pediatric in- and out-patients estimated the incidence to be 9.5% (95% CI 6.81, 12.26) in in-patients and 1.5% (95% CI 0.7, 3.03) in out-patients [6,7]

Drug Hypersensitivity reactions (DHRs) including true “drug allergy” represent up to one third of all ADRs and can be severe and life-threatening requiring prolonged hospitalization and associated healthcare costs [8]. DHRs are classified, according to their onset and the immune mechanism involved, into immediate-type DHR (IDHRs) or delayed-type DHRs (DDHRs). IDHRs occur

within an hour of drug exposure and are mediated by IgE antibodies generated against the drug or metabolite(s). On the other hand, DDHRs occur days or weeks after drug exposure and are IgG or T-cell-mediated [9,10]. Antibiotics are the most commonly prescribed drugs in children and they are the second leading cause of ADRs resulting in emergency department visit and/or hospital admission in children (18%) after cancer chemotherapy [11,12,13]. DHRs represent a major clinical problem because of their potential seriousness and high morbidity. In addition, labeling a child with antibiotic allergy without confirmation has its consequences to both the patient and public health [14]. Approximately 10% of children are reported by their parents to have antibiotic allergy and 75% of them are diagnosed before their third birthday [15,16]. Unfortunately, this is frequently incorrect and over-labeling of antibiotic allergy has been demonstrated to have a negative health impact both on the patient and the health care system. Unconfirmed childhood allergy labeling most often extends to the rest of the patients' life leading to unnecessarily depriving them from useful and safe drugs and exposing them to less safe and more expensive alternatives. In fact, studies have shown that when labeled children are challenged with the culprit drug, over 90% are able to tolerate the drug [17,18,19]. Current data shows that up to 10% of children are reported to have beta-lactam allergy and are the most common trigger of anaphylactic reactions in children [1,20]. The risk of fatal anaphylaxis due to penicillin use has been estimated at 0.0015–0.002% of treated patients [21,22]. Up to 75% of fatal drug-induced anaphylaxis in the United States are caused by penicillins, which corresponds to 500–1,000 annual fatality [23-26]. Prescribing medicines to children is challenging due to the lack of reliable safety data as a result of the limited number of clinical trials in the pediatric population. One example is dose. Dose calculation for pediatric patients based on weight and body surface area (BSA) can be both inaccurate and prone to errors. Children are not merely little adults; they have their own unique pharmacokinetics and pharmacodynamics and these parameters change dramatically especially during the first few years of life [27-31]. Dose estimation from adult studies can be extrapolated with allometric scaling but this may not always result in an optimal or safe dose due to the variability imposed by ontogeny.

In addition, “the pharmacological interaction of drugs with the immune system (p-i) hypothesis” postulates that drugs or their metabolites can directly and non-covalently interact and activate immune cells causing DHRs. Evidence also exist that supports the concept of drug-induced alteration in the self-peptide repertoire presented in the context of the major histocompatibility complex (MHC) molecules by antigen presenting cells to T-cells. This has provided explanation as to the role of human leukocyte antigen (HLA) genetic variation in the pathophysiology of DHRs (e.g., abacavir-induced DHRs). Understanding DHRs pathophysiology is crucial to the development and interpretation of in vitro tests for drug hypersensitivity as discussed further below.

**TABLE 1**  
**Classification of immune-mediated DHRs.**

Type	Mechanism	Example	Drugs most commonly involved with DHRs
I	IgE-mediated	Anaphylaxis, urticaria, bronchospasm, and rhinitis	Beta-lactam antibiotics, ACE inhibitors, NMBAs, radiocontrast media, NSAIDs, and opioids

Type	Mechanism	Example	Drugs most commonly involved with DHRs
II	IgG-mediated	Blood cell dyscrasia	Penicillins, sulfonamides, aromatic anticonvulsants, quinine, heparin, thiazides, and gold salts
III	IgG/M-mediated	SSLR, vasculitis	Cephalosporins (e.g., cefaclor), infliximab, allopurinol, and bupropion
IV	T-cell-mediated	DRESS, SJS, TEN, AGEP, ME, and FDE	Sulfonamides, nevirapine, aromatic anticonvulsants, NSAIDs, dapsone, allopurinol, abacavir, and minocycline

### Modeling in Drug Therapy

Many drug regulatory agencies around the world have recently issued mandates to promote drug development for children use that is evidence-based [31,32]. However, conducting a large-scale detailed pharmacokinetics/pharmacodynamics (PK/PD) trials in children is a huge undertake even for major pharmaceutical companies and might not be feasible. In the United States, The Best Pharmaceutical for Children Act (BPCA), which became a law in 2002, has been put forward to encourage the pharmaceutical industry to perform studies to improve evidence-based pediatric drug therapy ([NICHD, 2020](#)). Model-based studies and application of simulation and pharmacometrics for pediatric therapy has gained momentum in recent years ([Vinks et al., 2015](#)). Pharmacometrics applies quantitative mathematical models of physiology, pharmacology and pathology to predict pharmacokinetics (PK) and pharmacodynamics (PD) parameters for the purpose of assessing drug efficacy and safety ([Barrett et al., 2008](#)). This recent concept has been applied in pediatrics to evaluate the influence of growth and development on drug disposition and toxicity ([Anderson et al., 2006](#)). However, data supporting model-based evaluation of antimicrobial-induced hypersensitivity reactions has been scarce and current guidelines do highlight this problem [33-34].

Thus, the model system employed should be tailored around the putative pathogenesis of the ADR of interest ([Figure 1](#)). The principle of the lymphocyte toxicity assay (LTA) and the in vitro platelet toxicity assay (iPTA) tests is based on the hypothesis that DHRs are developed as a result of accumulation of toxic reactive metabolites (RMs) resulting in induction of necroptosis and release of intracellular “danger signals”, and haptentation of endogenous peptides that can be recognized by the immune system [35]. The LTT and BAT tests detect circulating drug-specific immune cells (lymphocytes and basophil, respectively), which are thought to mediate the immune reaction [36-39]. Role of the in vitro testing model is discussed further below.

### In vitro Testing Model

In vitro testing for DHRs has the advantage of carrying no potential harm to patients [40,41]. The selection of an in vitro diagnostic test for DHRs depends on the type of reaction (i.e., immediate vs delayed). Immediate IgE-mediated reactions are mediated by a specific IgE against the culprit drug and, therefore, quantification of those antibodies has been used to diagnose this type of reactions. Radioallergosorbent test (RAST), cellular fluorescent assay-IgE (CAP-IgE) and enzyme-linked immunosorbent assay (ELISA) have a good predictive value. A radioactive technique is no longer used but, “RAST” has become generic name for IgE quantification. These tests tend to have an excellent specificity but very poor sensitivity and have been validated only for a few very specific drug-induced reactions (i.e., classical allergy or Gell and Coombs Type I

Hypersensitivity) and only for a few drugs [41,42]. The basophil activation test (BAT) has been found useful in diagnosing immediate-type reactions to muscle relaxants, beta-lactam antibiotics and NSAIDs [43]. The lymphocyte transformation test (LTT) measures drug specific T-cells in the circulation and it has been found to be useful to aid diagnosis of delayed-type hypersensitivity reactions. However, due to its complicated and expensive procedure, its clinical utility has been limited to highly sophisticated research centers.

### **Conclusion**

In terms of drug development, use of modeling for assessment of drug safety for antimicrobials has been hampered by both a lack of suitable animal models and by a lack of understanding of the putative pathophysiology of DHRs. As our understanding of the fundamental biology of DHRs expands and our ability to develop humanized animal models increases it is hoped that this will enable better modeling of DHRs to antimicrobial therapy in children. This review summarizes the current state-of-the-art knowledge of model-based evaluation of DHRs to antimicrobials in children. Several key issues in the field have been highlighted, which include lack of animal model to study the molecular pathophysiology of DHRs and limited validated in vitro tests with good predictive values. We believe that further understanding of the exact pathophysiology underlying DHRs will allow the development of more predictive models to optimize the management of these ADRs.

### **References:**

1. Aberer W., Bircher A., Romano A., Blanca M., Campi P., Fernandez J., et al. (2003). Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. *Allergy* 58 (9), 854–863. 10.1034/j.1398-9995.2003.00279.x
2. Abuaf N., Rajoely B., Ghazouani E., Levy D. A., Pecquet C., Chabane H., et al. (1999). Validation of a flow cytometric assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy☆☆☆. *J. Allergy Clin. Immunol.* 104 (2 Pt 1), 411–418. 10.1016/s0091-6749(99)70386-6
3. Anderson B. J., Allegaert K., Holford N. H. G. (2006). Population clinical pharmacology of children: general principles. *Eur. J. Pediatr.* 165 (11), 741–746. 10.1007/s00431-006-0188-y
4. Araujo L., Demoly P. (2008). Macrolides allergy. *Curr. Pharm. Des.* 14 (27), 2840–2862. 10.2174/138161208786369812
5. Ariza A., Mayorga C., Bogas G., Barrionuevo E., Torres M. J., Doña I., et al. (2020). Advances and novel developments in drug hypersensitivity diagnosis. *Allergy* 75, 3112. 10.1111/all.14603
6. Barbaud A., Waton J., Herbeth B., Bursztejn A. C., Bollaert M., Schmutz J. L., et al. (2014). Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS). *J. Eur. Acad. Dermatol. Venereol.* 28 (4), 491–499. 10.1111/jdv.12130
7. Barrett J. S., Fossler M. J., Cadieu K. D., Gastonguay M. R. (2008). Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. *J. Clin. Pharmacol.* 48 (5), 632–649. 10.1177/0091270008315318
8. Elmurodova, A. . (2023). ROLE OF CYTOKINES IN THE DEVELOPMENT OF LIVER CIRRHOSIS, WHICH DEVELOPED AS A RESULT OF CHRONIC VIRAL HEPATITIS D. *Евразийский журнал медицинских и естественных наук*, 3(11), 217–221. извлечено от <https://in-academy.uz/index.php/EJMNS/article/view/23842/>

9. Elmurodova A.A. (2023). Viral Hepatitis Delta: An Underestimated Threat. *Texas Journal of Medical Science*, 26, 1–3. Retrieved from <https://zienjournals.com/index.php/tjms/article/view/4610>
10. Oblokulov Abdurashid Rakhimovich Mukhammadieva Musharraf Ibromkhimovna Sanokulova Sitara Avazovna Khadieva Dora Isakovna. (2023).
11. CLINICAL AND LABORATORY FEATURES OF SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH VIRAL LIVER CIRRHOSIS. *Journal of Advanced Zoology*, 44(S2), 3744–3750. Retrieved from
12. <http://www.jazindia.com/index.php/jaz/article/view/1716>
13. Mukhammadieva M.I. (2022). Modern clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis // *Texas Journal of Medical Science*. – 2022.- P. 86-90
14. 12.Abdulloev Mukhriddin Ziyodulloevich. (2023). Modern Therapy of Viral Hepatitis. *Texas Journal of Medical Science*, 26, 66–69. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4636>
15. Abdulloev Mukhriddin Ziyodulloevich. (2023). Modern Therapy of Viral Hepatitis. *Texas Journal of Medical Science*, 26, 66–69. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4636>
16. Mukhammadieva M.I. (2023). Вирус этиологияли жигар циррози беморларида спонтан бактериал перитонит билан асоратланишнинг профилактикаси ва давосини такомиллаштириш// *Oriental Renaissance: Innovative, educational, natural and social sciences*. -2023.-P.947-953.
17. Oblokulov A.R., M.I.Mukhammadieva.(2022). Clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis// *Academia Globe: Inderscience Research*.-2022.- P. 210-216.
18. .M. R., M. ., & S. A., S. . (2022). Features of the Course of Contagious Giardiasis Associated with Giardiasis. *Miasto Przyszłości*, 26, 186–189. Retrieved from <https://miastoprzyszlosci.com.pl/index.php/mp/article/view/464>
19. Sanokulova Sitara Avazovna. (2023). COVID-19 IN CHILDREN. *Academia Science Repository*, 4(06), 25–32. Retrieved from <https://academiascience.com/index.php/repo/article/view/843>
20. Sanokulova Sitara Avazovna. (2023). Acute Kidney Injury in Critically Ill Cirrhotic Patients with Spontaneous Bacterial Peritonitis. *Texas Journal of Medical Science*, 25, 65–70. Retrieved from <https://zienjournals.com/index.php/tjms/article/view/4502>
21. Sanokulova Sitara Avazovna. (2023). Factors of Development of Hepatorenal Syndrome in Patients with Liver Cirrhosis of Viral Etiology. *Texas Journal of Medical Science*, 26, 4–9. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4611>
22. Авазовна, С. С. . (2023). Факторы Развития Гепаторенального Синдрома У Больных Циррозом Печени Вирусной Этиологии. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 2(12), 1–8. Retrieved from <https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8673>
23. Санокуллова, Ситора Авазовна ОСОБЕННОСТИ ТЕЧЕНИЯ КОНТОГИОЗНЫХ ГЕЛЬМИНТОВ АССОЦИИРОВАННОГО С ЛЯМБЛИОЗОМ // *Orienss*. 2023. №2. URL: <https://cyberleninka.ru/article/n/ocobennosti-techeniya-kontogioznyh-gelmintov-assotsirovannogo-s-lyambliozom> (дата обращения: 12.12.2023).



24. Jalilova, A.S. (2022). THE SPREAD OF CIRRHOSIS OF THE LIVER BY ETIOLOGICAL FACTORS. *Oriental renaissance: Innovative, educational, natural and social sciences*, 2 (6), 253-257.\
25. A. A., E., A. S., D., & A., M. S. (2022). Modern Approaches to Treatment of Chronic Giardiasis. *Central Asian Journal of Medical and Natural Science*, 3(2), 102-105. Retrieved from <https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/631>
26. Облокулов, А., & Мухаммадиева, М. (2022). КЛИНИКО-ЛАБОРАТОРНАЯ ХАРАКТЕРИСТИКА СПОНТАННОГО БАКТЕРИАЛЬНОГО ПЕРИТОНИТА ПРИ ЦИРРОЗЕ ПЕЧЕНИ ВИРУСНОЙ ЭТИОЛОГИИ. *Журнал вестник врача*, 1(3), 66–69. извлечено от [https://inlibrary.uz/index.php/doctors\\_herald/article/view/2016](https://inlibrary.uz/index.php/doctors_herald/article/view/2016)
27. Oblokulova Z.I, Oblokulov A.R, & Jalilova A.S. (2022). Diagnostic Significance of Hepatic Fibrosis in Patients with Extrahepatic Chronic Viral Hepatitis C. *Central Asian Journal of Medical and Natural Science*, 3(3), 438-443. Retrieved from <https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/806>
28. Aslonova.M.R. (2022). Determination of suicidality against the background of Parasitic Diseases in children // *INTERNATIONAL JOURNAL OF PHILOSOPHICAL STUDIES AND SOCIAL SCIENCES*. – 2022.- P. 9-12.
29. Jalilova, A. S. (2022). Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients. *INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES*, 1(1), 41-44.
30. Mukhtarova Sh.A. (2022) Age-related features of clinical manifestations of giardiasis // *International journal of medical sciences and clinical research* 2022;17-21.
31. Jalilova A.S. (2022). FEATURES OF CLINICAL MANIFESTATIONS OF CYTOMEGALOVIRUS INFECTION IN CHILDREN. *International Journal of Medical Sciences And Clinical Research*, 2(09), 12–16. <https://doi.org/10.37547/ijmscr/Volume02Issue09-04>
32. Raximovich, O. A., Sadilloeyvna, J. A., Abdulloeyvna, M. S., & Farxodovich , R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. *Central Asian Journal of Medical and Natural Science*, 3(2), 289-294. <https://doi.org/10.17605/OSF.IO/9CFP6>
33. Жалилова А. С. Дилноза Саётовна Косимова. Клинико–Лабораторная Характеристика Пациентов С Covid-19 И Предиктор Антибактериальной Терапии // *CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES*. – 2021. – С. 81-86.
34. Abdulloeyvna, M. S. . (2023). Tez-Tez Kasal Bo'lgan Bolalarda O'tkir Respirator Kasalliklarning Klinik-Laboratoriya Xususiyatlari. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 2(12), 29–34. Retrieved from <https://sciencebox.uz/index.php/amaltibbiyot/article/view/8680>